Moore Capital Management LP Takes Position in Relay Therapeutics, Inc. $RLAY

Posted by George Bondi on Aug 31st, 2026

Moore Capital Management LP acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 414,005 shares of the company’s stock, valued at approximately $7,746,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of RLAY. Alphabet Inc. acquired a new position in Relay Therapeutics in the 2nd quarter worth approximately $26,382,000. California State Teachers Retirement System lifted its stake in Relay Therapeutics by 47.9% during the 1st quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock valued at $1,732,000 after acquiring an additional 56,422 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of Relay Therapeutics in the 2nd quarter valued at $1,323,000. Sanctuary Advisors LLC purchased a new stake in shares of Relay Therapeutics in the 2nd quarter valued at $1,995,000. Finally, Bank of America Corp DE increased its stake in shares of Relay Therapeutics by 86.1% in the first quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock worth $19,280,000 after acquiring an additional 896,746 shares during the period. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Transactions at Relay Therapeutics

In related news, CFO Thomas Catinazzo sold 187,163 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the transaction, the chief financial officer owned 177,461 shares of the company’s stock, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Peter Rahmer sold 50,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the transaction, the insider directly owned 225,857 shares of the company’s stock, valued at $4,311,610.13. The trade was a 18.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,414,147 shares of company stock worth $123,723,695 over the last quarter. Company insiders own 5.04% of the company’s stock.

Wall Street Analyst Weigh In

RLAY has been the subject of several recent research reports. Canaccord Genuity Group started coverage on shares of Relay Therapeutics in a report on Thursday, July 16th. They set a “buy” rating and a $29.00 target price for the company. The Goldman Sachs Group upped their price target on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Citigroup reaffirmed a “market outperform” rating on shares of Relay Therapeutics in a research report on Monday, August 10th. Zacks Research upgraded Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, Barclays boosted their price objective on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Read Our Latest Research Report on Relay Therapeutics

Relay Therapeutics Stock Performance

RLAY stock opened at $18.77 on Monday. The firm has a market cap of $4.11 billion, a PE ratio of -11.96 and a beta of 1.69. The firm’s fifty day moving average is $19.27 and its 200 day moving average is $14.79. Relay Therapeutics, Inc. has a one year low of $3.52 and a one year high of $21.27.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. Research analysts predict that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Relay Therapeutics

(Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.